ClinicalTrials.gov
public full text
Public Domain
Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure
The purpose of this study is to evaluate the efficacy and safety of mirabegron (a B3 adrenergic receptor agonist) in patients with pulmonary hypertension secondary to heart failure by conducting a randomized multicenter phase II placebo-controlled clinical trial.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Losartan in Decompensated Heart Failure#1104045
- Beta Blocker Therapy in Moderate to Severe COPD#839037
- GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD#801072
- Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System#875211
- Beta 3 Agonist Treatment in Heart Failure#837927
Record · ID 1138017
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive